Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT00846742

Age - N/A-21 Years Condition - Lymphoma: Hodgkin Gender - All Accepting Healthy Volunteers - No

Purpose

This phase II trial is studying how well combination chemotherapy with or without radiation therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride, vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy uses high-energy x-rays to kill cancer cells for those patients that still had residual cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may kill more cancer cells and allow doctors to save the part of the body where the cancer started.

Official Title

Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma

Stanford Investigator(s)

Neyssa Marina

Michael Link

Eligibility


Inclusion Criteria:

   - Histologically confirmed, previously untreated Hodgkin lymphoma.

   - Age: Participants must be 21 years of age or younger

   - Stage must be classified as one of the following:

Ann Arbor stage IA or IIA with:

   - Non-bulky mediastinal disease (< 33% mediastinal to thoracic ratio on CXR)

   - < 3 nodal regions involved on the same side of the diaphragm

   - No "E" lesion

   - Female patients who are post-menarchal must have a negative pregnancy test. Patients
   of reproductive potential must agree to use an effective contraceptive method.

   - Signed informed consent

   - If re-evaluation of a patient's disease shows intermediate risk features, the patient
   will be removed from the HOD08.

Exclusion Criteria:

   - Intermediate or High risk disease, defined as Stage IB, any III or IV or IA/IIA with
   "E" lesion(s), 3 or more nodal sites involved, or bulky mediastinal adenopathy

View More
View Less

Intervention(s):

radiation: Radiation Therapy

drug: Stanford V Chemotherapy

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Regina Dagher
650-725-4041

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine